Literature DB >> 8050180

Development of antibodies to hepatitis B virus surface antigen in bone marrow transplant recipient following treatment with peripheral blood lymphocytes from immunized donors.

Y Ilan1, A Nagler, D Shouval, A Ackerstein, R Or, J Kapelushnik, R Adler, S Slavin.   

Abstract

Bone marrow transplantation (BMT) recipients are immunosuppressed and are at risk for contracting severe infections. Recently, adoptive transfer of immunity against hepatitis B virus (HBV) was documented in BMT recipients receiving bone marrow from 'naturally' HBV-infected individuals who recovered spontaneously, or those transplanted with bone marrow cells obtained from actively immunized donors. Furthermore, reconstitution of the immune system in a BMT recipient who was a hepatitis surface antigen (HBsAg)+/HBV DNA+ carrier with HBV immune bone marrow cells led to clearance of the replicating virus, presumably through adoptive cell-mediated immunotherapy. We report three cases of induction of immunity to HBV by selective adoptive transfer by i.v. injection of peripheral blood lymphocytes (PBL) obtained from BMT donors who were actively immunized against HBV after harvesting of bone marrow. All three BMT recipients developed anti-HBs antibodies. In one BMT case in whom antibodies to HBsAg developed following adoptive transfer of immune PBL, a mild booster effect was documented in the BMT recipient upon immunization with a recombinant hepatitis B vaccine. The two remaining patients lost their antibodies to HBsAg in association with relapse of leukaemia. This immune manipulation may open the door to evaluation of adoptive transfer of immunity to HBV through selective transplantation of HBV immune lymphocytes in selected patients such as those with persistent HBV infection, as well as liver transplant recipients who require protection of the graft against HBV re-infection.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8050180      PMCID: PMC1534692          DOI: 10.1111/j.1365-2249.1994.tb06084.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  20 in total

1.  Designed transfer of specific immune responses with bone marrow transplantation.

Authors:  A Saxon; R Mitsuyasu; R Stevens; R E Champlin; H Kimata; R P Gale
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

Review 2.  Liver disease after human marrow transplantation.

Authors:  G B McDonald; H M Shulman; J L Wolford; G D Spencer
Journal:  Semin Liver Dis       Date:  1987-08       Impact factor: 6.115

3.  Adoptive transfer of immunity to hepatitis B virus after T cell-depleted allogeneic bone marrow transplantation.

Authors:  Y Ilan; A Nagler; R Adler; E Naparstek; R Or; S Slavin; C Brautbar; D Shouval
Journal:  Hepatology       Date:  1993-08       Impact factor: 17.425

4.  Pneumococcal vaccination of recipients of bone marrow transplants.

Authors:  D J Winston; W G Ho; G Schiffman; R E Champlin; S A Feig; R P Gale
Journal:  Arch Intern Med       Date:  1983-09

5.  Fulminant hepatitis due to reactivation of chronic hepatitis B virus infection after allogeneic bone marrow transplantation.

Authors:  E A Pariente; A Goudeau; F Dubois; C Degott; E Gluckman; A Devergie; C Brechot; C Schenmetzler; J Bernuau
Journal:  Dig Dis Sci       Date:  1988-09       Impact factor: 3.199

Review 6.  The kinetics of immune reconstitution after human marrow transplantation.

Authors:  L G Lum
Journal:  Blood       Date:  1987-02       Impact factor: 22.113

7.  Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine.

Authors:  P Ljungman; E Fridell; B Lönnqvist; P Bolme; M Böttiger; G Gahrton; A Linde; O Ringdén; B Wahren
Journal:  J Infect Dis       Date:  1989-04       Impact factor: 5.226

8.  Adoptive transfer of immunity to hepatitis B virus in mice by bone marrow transplantation from immune donors.

Authors:  D Shouval; R Adler; Y Ilan
Journal:  Hepatology       Date:  1993-06       Impact factor: 17.425

9.  Abnormal T-cell activation in chronic hepatitis B viral infection: a consequence of monocyte dysfunction?

Authors:  K T Nouri-Aria; S Magrin; G J Alexander; M G Anderson; R Williams; A L Eddleston
Journal:  Immunology       Date:  1988-08       Impact factor: 7.397

10.  Antigen-driven long term-cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long-term as functional memory T cells.

Authors:  M A Cheever; D B Thompson; J P Klarnet; P D Greenberg
Journal:  J Exp Med       Date:  1986-05-01       Impact factor: 14.307

View more
  4 in total

1.  Control of hepatitis B virus infection in hematopoietic stem cell recipients after receiving grafts from vaccinated donors.

Authors:  M Lindemann; M Koldehoff; M Fiedler; A Schumann; H D Ottinger; F M Heinemann; M Roggendorf; P A Horn; D W Beelen
Journal:  Bone Marrow Transplant       Date:  2015-10-26       Impact factor: 5.483

Review 2.  The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection.

Authors:  Stephan Menne; Paul J Cote
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

3.  Development of immunity against hepatitis B virus after donor lymphocyte infusion in a peripheral blood stem cell transplantation recipient with chronic hepatitis B.

Authors:  L-T Chiang; M Yao; B-S Ko; C-H Chen
Journal:  Infection       Date:  2011-05-05       Impact factor: 3.553

4.  Advances in immunomodulating therapy of HBV infection.

Authors:  Chee-Kin Hui; George Kk Lau
Journal:  Int J Med Sci       Date:  2005-01-05       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.